NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) News Today $13.60 -0.05 (-0.37%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$13.26▼$13.8050-Day Range$11.74▼$15.3252-Week Range$6.40▼$28.35Volume761,200 shsAverage Volume780,267 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice Target$43.57 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Media Mentions By Week DAWN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.340.55▲Average Medical News Sentiment DAWN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼33▲DAWN Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 4.1%americanbankingnews.com - June 2 at 6:38 AMHead-To-Head Contrast: Day One Biopharmaceuticals (DAWN) and The Competitionamericanbankingnews.com - June 1 at 8:14 AMDay One to Participate in the Goldman Sachs 44th Annual Healthcare Conferencefinance.yahoo.com - May 30 at 8:17 AMPromising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meetingbaystreet.ca - May 26 at 10:35 AMCitigroup Inc. Reduces Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)marketbeat.com - May 26 at 5:37 AMCORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - May 26 at 12:34 AMDay One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - May 25 at 7:29 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Strong Trading Volumeamericanbankingnews.com - May 24 at 7:46 AMInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $12,529.60 in Stockamericanbankingnews.com - May 20 at 7:52 AMJeremy Bender Sells 3,104 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stockamericanbankingnews.com - May 19 at 9:48 AMHC Wainwright & Co. Reiterates Day One Biopharmaceuticals (DAWN) Buy Recommendationmsn.com - May 18 at 7:27 PMH.C. Wainwright Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - May 18 at 9:26 AMAnalysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $45.17americanbankingnews.com - May 17 at 1:34 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of "Moderate Buy" by Analystsmarketbeat.com - May 14 at 1:20 AMUnusual Put Option Trade in Day One Biopharmaceuticals (DAWN) Worth $116.90Kmsn.com - May 9 at 12:50 AMCapital One Financial Weighs in on Day One Biopharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:DAWN)americanbankingnews.com - May 6 at 2:46 AMEquities Analysts Issue Forecasts for Day One Biopharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:DAWN)americanbankingnews.com - May 5 at 4:28 AMDay One Biopharmaceuticals, Inc. Expected to Earn Q1 2024 Earnings of ($0.59) Per Share (NASDAQ:DAWN)americanbankingnews.com - May 5 at 3:55 AMQ2 2023 Earnings Estimate for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Issued By HC Wainwrightamericanbankingnews.com - May 4 at 7:30 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) to Post Q2 2023 Earnings of ($0.58) Per Share, Wedbush Forecastsamericanbankingnews.com - May 4 at 7:30 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 10.3%americanbankingnews.com - May 3 at 6:40 AMNeedham Reiterates Day One Biopharmaceuticals (DAWN) Buy Recommendationmsn.com - May 2 at 6:54 PMNeedham Reaffirms Their Buy Rating on Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - May 2 at 1:54 PMPiper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - May 2 at 8:54 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 6.1% in Aprilamericanbankingnews.com - May 2 at 5:50 AMDay One Reports First Quarter 2023 Financial Results and Corporate Progressfinance.yahoo.com - May 1 at 9:56 AMBank of America Downgrades Day One Biopharmaceuticals (NASDAQ:DAWN) to Underperformamericanbankingnews.com - April 27 at 3:00 AMDay One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - April 26 at 1:13 PMB of A Securities Downgrades Day One Biopharmaceuticals (DAWN)msn.com - April 25 at 8:45 PMDay One Biopharma falls 14% as Bank of America downgradesmsn.com - April 25 at 10:44 AMWhat 5 Analyst Ratings Have To Say About Day One Biopharmaceuticalmarkets.businessinsider.com - April 25 at 10:44 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $43.57 Consensus Target Price from Analystsamericanbankingnews.com - April 22 at 1:38 AMLeaked: Apple's Secret Health Play Could Push Out Smaller Appsfinance.yahoo.com - April 21 at 5:45 PMA Daily Journal For iPhone: Apple Weighs Day One-Like Health App For iPhone Usersfinance.yahoo.com - April 21 at 12:44 PMJonesTrading Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - April 20 at 12:52 PMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Growth in Short Interestamericanbankingnews.com - April 20 at 7:34 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - April 19 at 2:19 AMDay One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congressfinance.yahoo.com - April 12 at 8:52 AMDay One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congressfinance.yahoo.com - April 12 at 8:52 AMDay One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concernsseekingalpha.com - April 7 at 7:37 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $44.00americanbankingnews.com - April 7 at 3:58 AMAnalyst Expectations for Day One Biopharmaceutical's Futuremsn.com - April 5 at 5:56 PMNeedham Maintains Day One Biopharmaceuticals (DAWN) Buy Recommendationmsn.com - April 5 at 5:56 PMDay One Biopharmaceuticals, Inc. Forecasted to Post FY2023 Earnings of ($2.66) Per Share (NASDAQ:DAWN)americanbankingnews.com - April 2 at 1:52 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) to Post FY2023 Earnings of ($2.66) Per Share, Oppenheimer Forecastsmarketbeat.com - March 31 at 6:51 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increaseamericanbankingnews.com - March 29 at 5:34 AMBrokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $44.14americanbankingnews.com - March 28 at 2:20 AMDay One Biopharmaceuticals Becomes Oversold (DAWN)nasdaq.com - March 26 at 12:12 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - March 25 at 2:17 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 4.5%americanbankingnews.com - March 24 at 7:40 AM Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Kura Oncology News Today Kiniksa Pharmaceuticals News Today Avid Bioservices News Today Innoviva News Today Rhythm Pharmaceuticals News Today Structure Therapeutics News Today 23andMe News Today uniQure News Today EQRx News Today Merus News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:DAWN) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.